Nonalcoholic Fatty Liver Disease Clinical Trials in Wuhan, Hubei

To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease